Locally Advanced Unresectable or Metastatic Solid Tumors Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting locally advanced unresectable or metastatic solid tumors clinical trials across 4 countries. Studies span Phase 1, Phase 2. Top locations include Austin, Texas, United States, Hangzhou, Zhejiang, China, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Locally Advanced Unresectable or Metastatic Solid Tumors Trials at a Glance

7 actively recruiting trials for locally advanced unresectable or metastatic solid tumors are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in Austin, Hangzhou, and Beijing. Lead sponsors running locally advanced unresectable or metastatic solid tumors studies include Innovent Biologics (Suzhou) Co. Ltd., NEOK Bio, Inc., and Hangzhou Sumgen Biotech Co., Ltd..

Browse locally advanced unresectable or metastatic solid tumors trials by phase

Treatments under study

About Locally Advanced Unresectable or Metastatic Solid Tumors Clinical Trials

Looking for clinical trials for Locally Advanced Unresectable or Metastatic Solid Tumors? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Unresectable or Metastatic Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Unresectable or Metastatic Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.150 enrolled1 locationNCT07646626
Recruiting
Phase 1

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
NEOK Bio, Inc.155 enrolled8 locationsNCT07612189
Recruiting
Phase 1

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
NEOK Bio, Inc.155 enrolled8 locationsNCT07612176
Recruiting
Phase 1

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.470 enrolled39 locationsNCT05458219
Recruiting
Phase 1

SG1906 for CLDN18.2-Positive Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.60 enrolled9 locationsNCT05857332
Recruiting
Phase 1

A Study of TXN10128 in Subjects With Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
Txinno Bioscience Inc.96 enrolled6 locationsNCT05978492
Recruiting
Phase 1Phase 2

A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.368 enrolled6 locationsNCT05636215